Expression of BCL-6 Protein, CD138/syndecan-1 (syn-1), and LMP-1 in AIDS-PCNSL and AIDS-PEL
| Case* . | Diagnosis . | Immunohistochemistry† . | Viral Infections . | c-MYC . | BCL-6 . | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| BCL-6 (%) . | Syn-1 (%) . | LMP-1 (%) . | EBV‡ . | KSHV‡ . | Genetic Lesions . | Rearrangements . | Mutations . | |||
| 28 | AIDS-PCNSL | LNCCL | 50-75 | 0 | 0 | + | − | − | ND | − |
| 29 | AIDS-PCNSL | LNCCL | >75 | 0 | 0 | + | − | − | ND | + |
| 30 | AIDS-PCNSL | LNCCL | 50-75 | 0 | 0 | + | − | − | ND | + |
| 31 | AIDS-PCNSL | LNCCL | 50-75 | 0 | 0 | + | − | − | ND | − |
| 32 | AIDS-PCNSL | IBLP | 0 | 10-25 | 0 | + | − | − | ND | − |
| 33 | AIDS-PCNSL | IBLP | 0 | <10 | 10-25 | + | − | − | ND | − |
| 34 | AIDS-PCNSL | IBLP | 0 | 0 | 50-75 | + | − | − | ND | − |
| 35 | AIDS-PCNSL | IBLP | 0 | 0 | 10-25 | + | − | − | ND | + |
| 36 | AIDS-PEL | 0 | >75 strong | 0 | + | + | − | − | + | |
| 37 | AIDS-PEL | 0 | >75 strong | <10 | + | + | − | − | + | |
| 38 | AIDS-PEL | 0 | >75 strong | 0 | − | + | − | − | + | |
| 39 | AIDS-PEL | 0 | >75 strong | 0 | − | + | − | − | + | |
| 40 | AIDS-PEL | 0 | >75 strong | 0 | + | + | − | − | − | |
| HBL-6 | AIDS-PEL | 0 | >75 strong | <10 | + | + | − | − | + | |
| BC-1 | AIDS-PEL | 0 | >75 strong | 0 | + | + | − | − | + | |
| BC-2 | AIDS-PEL | 0 | >75 strong | 0 | + | + | − | − | + | |
| CRO-AP/2 | AIDS-PEL | 0 | >75 strong | 10-25 | + | + | − | − | + | |
| BC3 | AIDS-PEL | 0 | >75 strong | 0 | − | + | − | − | − | |
| BCBL-1 | AIDS-PEL | 0 | >75 strong | 0 | − | + | − | − | + | |
| Case* . | Diagnosis . | Immunohistochemistry† . | Viral Infections . | c-MYC . | BCL-6 . | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| BCL-6 (%) . | Syn-1 (%) . | LMP-1 (%) . | EBV‡ . | KSHV‡ . | Genetic Lesions . | Rearrangements . | Mutations . | |||
| 28 | AIDS-PCNSL | LNCCL | 50-75 | 0 | 0 | + | − | − | ND | − |
| 29 | AIDS-PCNSL | LNCCL | >75 | 0 | 0 | + | − | − | ND | + |
| 30 | AIDS-PCNSL | LNCCL | 50-75 | 0 | 0 | + | − | − | ND | + |
| 31 | AIDS-PCNSL | LNCCL | 50-75 | 0 | 0 | + | − | − | ND | − |
| 32 | AIDS-PCNSL | IBLP | 0 | 10-25 | 0 | + | − | − | ND | − |
| 33 | AIDS-PCNSL | IBLP | 0 | <10 | 10-25 | + | − | − | ND | − |
| 34 | AIDS-PCNSL | IBLP | 0 | 0 | 50-75 | + | − | − | ND | − |
| 35 | AIDS-PCNSL | IBLP | 0 | 0 | 10-25 | + | − | − | ND | + |
| 36 | AIDS-PEL | 0 | >75 strong | 0 | + | + | − | − | + | |
| 37 | AIDS-PEL | 0 | >75 strong | <10 | + | + | − | − | + | |
| 38 | AIDS-PEL | 0 | >75 strong | 0 | − | + | − | − | + | |
| 39 | AIDS-PEL | 0 | >75 strong | 0 | − | + | − | − | + | |
| 40 | AIDS-PEL | 0 | >75 strong | 0 | + | + | − | − | − | |
| HBL-6 | AIDS-PEL | 0 | >75 strong | <10 | + | + | − | − | + | |
| BC-1 | AIDS-PEL | 0 | >75 strong | 0 | + | + | − | − | + | |
| BC-2 | AIDS-PEL | 0 | >75 strong | 0 | + | + | − | − | + | |
| CRO-AP/2 | AIDS-PEL | 0 | >75 strong | 10-25 | + | + | − | − | + | |
| BC3 | AIDS-PEL | 0 | >75 strong | 0 | − | + | − | − | − | |
| BCBL-1 | AIDS-PEL | 0 | >75 strong | 0 | − | + | − | − | + | |
Abbreviations: syn-1, CD138/syndecan-1; LNCCL, large noncleaved cell lymphoma; IBLP, immunoblastic lymphoma plasmacytoid; LMP-1, latent membrane protein-1; EBV, Epstein-Barr virus; KSHV, Kaposi's sarcoma associated herpesvirus; ND, not done; +, positive; −, negative.
Pathologic samples derived from patients are indicated by numbers; cell lines are indicated by their conventional denomination.
The percentage of BCL-6, CD138/syndecan-1, and LMP-1+ neoplastic cells was assigned to one of the following categories: 0, less than 10%, 10% to 25%, 25% to 50%, 50% to 75%, and greater than 75%.
Tumor cell infection as defined by a combination of in situ hybridization, Southern blot analysis, and PCR studies.